

Creso Pharma Ltd

10:00 07 Oct 2020

Creso Pharma appoints Canopy Growth Corp founder and ex-CEO Bruce Linton as strategic advisor

Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) has appointed NYSE-listed Canopy Growth Corp (NYSE:CGC) founder and former chief executive officer Bruce Linton as strategic advisor.

Linton is one of the world's leading cannabis executives and an accomplished entrepreneur, with extensive sector experience as a founder, CEO, board member and adviser to a number of global cannabis companies.

He founded Canopy Growth and turned it into the first cannabis producing company listed on the New York Stock Exchange, with a peak market capitalisation of US\$15 billion during his six-year tenure.

Deep network of industry contacts

CPH chief executive officer Miri Halperin Wernli said: "Bruce brings a wealth of invaluable knowledge and a deep network of cannabis industry contacts to Creso Pharma and we anticipate that his appointment will greatly assist us in achieving our near term operational milestones and longer-term goals.

"We continue to target international distribution agreements in a number of new markets and progress product development initiatives that will unlock considerable shareholder value. We look forward to providing further updates in the near-term."

Shape strategy

As strategic advisor, Linton will leverage his connections, expertise and influence in the industry to consult and work closely with Creso Pharma's board to shape the company's long-term strategy and various near-term corporate and operational initiatives.

Linton believes Creso Pharma is in an optimal position to excel internationally and continue to develop innovative products to complement its existing portfolio.

He says he was attracted to Creso Pharma by its unique IP, established global distribution footprint and robust product pipeline targeting distinct categories.

First cannabis producing company on NYSE

The new strategic advisor has extensive experience in the sector.


At Canopy Growth, he secured 16 rounds of financing of more than US\$5 billion in public capital markets and private placements and was involved in more than 30 merger and acquisitions.

After leaving Canopy Growth in 2019, Linton led direct investments into the sector and has held both management

Price: 0.195

Market Cap: \$185.94 m

1 Year Share Price Graph



March 2020 September 2020 March 2021

Share Information

Code: CPH

Listing: ASX

52 week High Low
0.47 0.024

Sector: Cannabis

Website: cresopharma.com

Company Synopsis:

Creso Pharma Limited (ASX:CPH, FRA:1X8 OTCMKTS:COPHF) brings the best of cannabis to better the lives of people and animals.

action@proactiveinvestors.com.au

positions and strategic advisory roles.

He is the executive chair of Gage Cannabis Co and the co-chairman of technology company Martello Technologies Group Inc (CVE:MTLO).

Linton is also the co-founder of Ruckify Software.

He has also worked extensively with international institutions such as the World Bank and has diversified into the psychedelic drug space as director of psychedelic-inspired medicine company Mind Medicine Inc.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).